pill Obicetrapib represents a significant advancement in cardiovascular health management. In a Phase 3 clinical trial, this innovatives medication demonstrated remarkable efficacy, achieving a 32.6% reduction in low-density lipoprotein (LDL) cholesterol and a 33.5% decrease in lipoprotein(a) [Lp(a)] levels within just 12 weeks . These findings are particularly noteworthy as elevated Lp(a) is often associated with an increased risk of heart disease and presents challenges in treatment . Thus, Obicetrapib not only addresses traditional cholesterol concerns but also targets this less commonly managed risk factor.
The study,which known as the BROADWAY trial, tested a once-daily oral drug called Obicetrapib. Results showed that it significantly reduced levels of LDL cholesterol and lipoprotein(a), or Lp(a). Both are key contributors to heart disease and are often difficult to manage.
Stephen Nicholls, Director of Monash University’s Victorian Heart Institute and Monash Health’s Victorian Heart Hospital, as a late-breaking clinical study at the European Atherosclerosis Society Congress in Glasgow, UK, and published in the New England Journal of Medicine (NEJM).
Medical experts have known for years that lowering LDL-C helps prevent future heart problems. Despite this, many treatment guidelines still recommend starting with a single drug, a statin, and only adding another drug if it doesn’t work. This slow approach might seem cautious, but in real life, it often takes too long. Many patients don’t follow up regularly. Others don’t get the extra medication they need in time. And that delay can cost lives.
A later trial on which Ray presented data, called TANDEM, utilized a fixed-dose combination of ezetimibe and obicetrapib. Ray expounded on these results and the optimism that they inspired in investigators.
“The two together gave you 48% lowering of LDL. More patients got to goal on a background of statin therapy; 70% of patients were getting to these really low targets that we now aim for below 55 in our patients,” Ray told HCPLive. “And we also saw LP(a) reductions as well with no safety signal.”
CETP inhibitors, Ray anticipates little to no uncertainty in clinicians utilizing obicetrapib should it be approved for cardiovascular disease prevention.
Moreover, the convenience of a once-daily dosage enhances patient adherence to treatment regimens . The BROADWAY trial further confirmed that Obicetrapib is well-tolerated among participants, making it an appealing option for individuals at high risk of heart attack or stroke. As cardiovascular diseases continue to pose significant public health challenges globally, the introduction of such effective and user-friendly medications could lead to improved health outcomes and potentially lower healthcare costs associated with cardiac events.
Read more
Airports Under Watch: Where Measles Cases Have Been Detected Vance Boelter apprehended in assassination of DFL House leader Melissa Hortman
Sara H
Also on site :